Catheter Precision, Inc. VTAK

Catheter Precision expands LockeT commercialization across Latin America after successful launch in Brazil. Latin American expansion for LockeT offers moderate revenue growth potential without fundamentally altering company trajectory.

Catheter Precision achieves commercial milestones via deals with Cardinal Health and Johns Hopkins plus first VIVO system placement in Germany. Major partnerships and European expansion point to significant commercial growth and market reach for VTAK.

Catheter Precision, Inc. (VTAK) reported record revenues for its Flyte product in July. Record revenues for Flyte point to improved product sales that may support near-term financial results.

Catheter Precision (VTAK) reported record preliminary Q2 revenue above $1 million. Record revenue beat signals sales growth and may lift near-term sentiment and valuation.

Catheter Precision, Inc. announced issuance of two key patents. Patent grants strengthen IP protection and may support product development and competitive positioning.

Catheter Precision, Inc. received allowance of key intellectual property. IP allowance strengthens patent position and supports future product development.

Catheter Precision, Inc. (VTAK), operating as Flyte, completed a strategic investment in Volato (SOAR). Strategic investment by VTAK in SOAR may moderately affect company's financials and positioning.

Catheter Precision, Inc. (VTAK) reported 200% revenue growth and completed its transformative acquisition of Flyte. 200% revenue growth plus completion of a transformative acquisition signals fundamental strategic expansion and improved competitive positioning.

Catheter Precision, Inc. (VTAK) will attend the 47th Annual Heart Rhythm Society Meeting to share new clinical data on its technologies. Sharing new clinical data at a premier cardiology conference boosts VTAK's visibility, validates products, and could drive partnerships or investment.

Catheter Precision, Inc. (VTAK) secures U.S. Patent Allowance for foundational surgical technology, establishing powerful IP portfolio and accelerating scalable growth strategy. Patent allowance on foundational surgical technology strengthens IP, enhances competitive edge, and accelerates VTAK's growth trajectory.

Catheter Precision, Inc. (VTAK) shareholders approved the definitive agreement to acquire 100% of Fly Flyte Inc. Shareholder approval advances a major acquisition that could expand VTAK's operations and market position.

Catheter Precision, Inc. (VTAK) announces accepted publication in a leading European medical journal. Accepted publication validates technology and enhances credibility in competitive medical device market.

Catheter Precision, Inc. (VTAK) announces new clinical data on its LockeT catheter system accepted for publication in a leading electrophysiology journal. Acceptance of LockeT data in a leading electrophysiology journal validates the technology, enhances credibility, and could drive partnerships and investor interest.

Catheter Precision, Inc. (VTAK) reported 2025 results and provided updates on strategic expansion. 2025 results combined with strategic expansion updates indicate significant moves that could alter VTAK's market trajectory and investor sentiment.

Catheter Precision, Inc. (VTAK) launches Flyte hops in Florida to meet accelerating demand. Florida expansion via Flyte hops directly addresses surging demand, signaling major growth in market reach and revenue potential.

Catheter Precision, Inc. (VTAK) secured up to $88 million in strategic institutional financing commitments to fund accelerated growth. Up to $88 million in strategic financing commitments provide transformative capital to accelerate growth and redefine VTAK's competitive position.

Catheter Precision, Inc. (VTAK) announced a definitive merger agreement to acquire 100% of Fly Flyte Inc. The definitive merger to acquire Fly Flyte Inc. represents a major strategic expansion with potential to significantly alter VTAK's operations and market position.

Creatd Inc. (CRTD) sold its remaining 80% stake in Fly Flyte to NYSE-listed Catheter Precision Inc. (VTAK), securing significant cash and equity position. VTAK gains full ownership of Fly Flyte through acquisition of the remaining 80% stake, marking a major strategic expansion.

Catheter Precision, Inc. (VTAK) announces its LockeT Suture Retention Device will be featured in live cases at the ISLAA 2026 conference. Live case demonstrations of the LockeT device at ISLAA 2026 offer moderate validation and visibility, influencing Catheter Precision's competitive positioning and investor sentiment.

Catheter Precision, Inc. (VTAK) announced the strategic sale of non-core assets to strengthen its balance sheet and accelerate growth in its electrophysiology business. Strategic divestiture of non-core assets bolsters finances and refocuses on high-growth electrophysiology, significantly enhancing future performance and investor sentiment.

Catheter Precision, Inc. has secured up to $36.5 million in strategic institutional financing aimed at accelerating its growth. This funding will support the company's initiatives in developing its catheter-based technologies and expanding its market presence. The financing is expected to enhance operational capabilities and drive innovation within the company. The strategic financing is likely to significantly impact the company's growth trajectory and market positioning.

Catheter Precision, Inc.'s LockeT Suture Retention Device will be showcased in live cases at the upcoming Scripps’ Structural Heart Intervention and Imaging 2026 Conference. This event highlights advancements in structural heart interventions and imaging technologies, providing a platform for demonstrating innovative medical devices. Showcasing the LockeT device at a prominent conference is likely to enhance visibility and credibility, potentially leading to increased adoption and market interest.

Catheter Precision, Inc. (VTAK) has reported increased momentum for its LockeT device, highlighted by new hospital approvals and a strong outlook for adoption in Q1. The company is experiencing a positive trend in the acceptance of its technology, which is expected to enhance its market position and drive future growth. New hospital approvals and strong adoption outlook are likely to significantly impact future performance and investor sentiment.

Catheter Precision, Inc. has received its first purchase order for the LockeT system in Germany, marking a significant milestone for the company as it expands its market presence in Europe. This order is expected to enhance the company's growth trajectory and strengthen its position in the medical technology sector. The first purchase order in Germany indicates a significant strategic move that could enhance market penetration and investor sentiment.

Catheter Precision, Inc. (VTAK) has received a new purchase order for its VIVO system from a leading hospital in Slovenia. This order signifies the growing adoption of the VIVO technology in international markets, enhancing the company's presence in Europe and potentially boosting its revenue streams. The new purchase order indicates significant market expansion and potential revenue growth for Catheter Precision.

Catheter Precision, Inc. (VTAK) has announced the expansion of its LockeT technology into an eighth European country following the receipt of a CE Mark. This expansion signifies the company's ongoing commitment to enhancing its market presence in Europe and improving patient care through innovative catheter technology. The expansion into additional European markets is a significant strategic move that could enhance revenue and market positioning.

Catheter Precision, Inc. has secured a tender from a leading hospital in Hungary, marking a significant step in expanding its market presence in Europe. This partnership is expected to enhance the company's operational capabilities and strengthen its position in the medical technology sector. Securing a tender from a leading hospital indicates a significant strategic move that could enhance market presence and investor sentiment.

Catheter Precision, Inc. has launched its innovative LockeT technology in Switzerland, aiming to enhance cardiac mapping and ablation procedures. This product introduction is expected to improve patient outcomes and streamline workflows for healthcare providers. The company is positioning itself to expand its market presence in Europe with this strategic move. The launch of LockeT in Switzerland represents a significant strategic move that could enhance the company's competitive positioning and market reach.

Catheter Precision, Inc. (VTAK) has gained a significant advantage following a historic decision to provide reimbursement for electrophysiology procedures in Ambulatory Surgery Centers (ASCs). This development opens up new opportunities for the company's LockeT device, which is designed for precise cardiac mapping and ablation. The reimbursement approval is expected to enhance the adoption of the LockeT device, potentially leading to increased revenue and market presence for Catheter Precision. The reimbursement approval for electrophysiology procedures in ASCs is likely to significantly enhance the market potential and adoption of the LockeT device.

Catheter Precision, Inc. has successfully launched its LockeT system in South Africa, marking a significant step in expanding its market presence. The LockeT system is designed to enhance catheter-based procedures, and its introduction is expected to improve patient outcomes and operational efficiency in the region. This launch aligns with the company's strategy to broaden its international footprint and leverage innovative technologies in the medical field. The successful launch of the LockeT system in South Africa is a major strategic move that could significantly enhance market presence and investor sentiment.